6AP.F - Aquinox Pharmaceuticals, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
2.0680
+0.0550 (+2.73%)
As of 9:15AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close2.0130
Open2.0680
Bid2.0810 x 53100
Ask2.1280 x 51700
Day's Range2.0680 - 2.0680
52 Week Range1.8100 - 13.2900
Volume125
Avg. Volume5
Market Cap50.426M
Beta (3Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.8150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory
    Zacks11 months ago

    Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory

    Aquinox Pharmaceuticals, Inc. (AQXP) has been on a bit of a cold streak lately

  • Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today
    Motley Foollast year

    Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today

    One of these stocks plummeted nearly 85%.

  • Failed Trial Pushed Aquinox Down almost 83% This Morning
    Market Realistlast year

    Failed Trial Pushed Aquinox Down almost 83% This Morning

    Today, Aquinox (AQXP) announced that its late-stage investigational drug, the once-daily oral therapy rosiptor, failed to demonstrate a statistically significant benefit over placebo for IC (interstitial cystitis) or BPS (bladder pain syndrome) in the Phase 3 LEADERSHIP 301 clinical trial. Pursuant to this announcement, Aquinox stock crashed from $15.31 yesterday to $2.43 this morning. Aquinox may have to forego a $25 million of upfront payment, $60 million of development milestone payments, and $70 million of commercial milestone payments that it would have otherwise received based on its exclusive licensing agreement with Astellas Pharma.